Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations

Oncogene

Volumn 35, Issue 10, 2016, Pages 1324-1327

  Golmard, L ^a,b   Delnatte, C ^c   Lauge A ^a   Moncoutier, V ^a   Lefol, C ^a   Abidallah, K ^a   Tenreiro, H ^a   Copigny, F ^a   Giraudeau, M ^a   Guy, C ^a   Barbaroux, C ^a   Amorim, G ^a   Briaux, A ^a   Guibert, V ^c   Tarabeux, J ^a,b   Caputo, S ^a   Collet, A ^a   Gesta, P ^d   Ingster, O ^e   Stern, M H ^a,b   Rouleau, E ^a   De Pauw, A ^a   Gauthier Villars, M ^a   Buecher, B ^a   Bezieau S ^c,f   Stoppa Lyonnet, D ^a,b,g   Houdayer, C ^a,b,h   more..

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d Oncogénétique Poitou Charentes   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ DE NANTES   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SUSCEPTIBILITY; FAMILY HISTORY; FEMALE; GENE DELETION; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; INDEL MUTATION; MAJOR CLINICAL STUDY; MOSAICISM; MUTATION RATE; OVARY CANCER; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; BREAST TUMOR; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; OVARY TUMOR; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS;

EID: 84961197202     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.181     Document Type: Article

References (32)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-792.
3. Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105: 812-822.
4. Caputo S, Benboudjema L, Sinilnikova O, Rouleau E, Béroud C, Lidereau R, et al. Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. Nucleic Acids Res 2012; 40: D992-D1002.
5. Tesoriero A, Andersen C, Southey M, Somers G, McKay M, Armes J, et al. De novo BRCA1 mutation in a patient with breast cancer and an inherited BRCA2 mutation. Am J Hum Genet 1999; 65: 567-569.
6. Edwards E, Yearwood C, Sillibourne J, Baralle D, Eccles D. Identification of a de novo BRCA1 mutation in a woman with early onset bilateral breast cancer. Fam Cancer 2009; 8: 479-482.
7. Kwong A, Ng EK, Tang EY, Wong CL, Law FB, Leung CP, et al. A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer. Fam Cancer. 2011; 10: 233-237.
8. Garcia-Casado Z, Romero I, Fernandez-Serra A, Rubio L, Llopis F, Garcia A, et al. A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer. BMC Med Genet 2011; 12: 134.
9. De Leeneer K, Coene I, Crombez B, Simkens J, Van den Broecke R, Bols A, et al. Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing. Breast Cancer Res Treat 2012; 132: 87-95.
10. Delon I, Taylor A, Molenda A, Drummond J, Oakhill K, Girling A, et al. A germline mosaic BRCA1 exon deletion in a woman with bilateral basal-like breast cancer. Clin Genet. 2013; 84: 297-299.
11. van der Luijt RB, van Zon PH, Jansen RP, van der Sijs-Bos CJ, Wárlám-Rodenhuis CC, Ausems MG. De novo recurrent germline mutation of the BRCA2 gene in a patient with early onset breast cancer. J Med Genet 2001; 38: 102-105.
12. Robson M, Scheuer L, Nafa K, Ellis N, Offit K. Unique de novo mutation of BRCA2 in a woman with early onset breast cancer. J Med Genet 2002; 39: 126-128.
13. Hansen TV, Bisgaard ML, Jønson L, Albrechtsen A, Filtenborg-Barnkob B, Eiberg H, et al. Novel de novo BRCA2 mutation in a patient with a family history of breast cancer. BMC Med Genet 2008; 9: 58.
14. Marshall M, Solomon S, Lawrence Wickerham D. Case report: de novo BRCA2 gene mutation in a 35-year-old woman with breast cancer. Clin Genet 2009; 76: 427-430.
15. Diez O, Gutiérrez-Enríquez S, Mediano C, Masas M, Saura C, Gadea N, et al. A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer. Breast Cancer Res Treat 2010; 121: 221-225.
16. Ripa R, Bisgaard ML, Bülow S, Nielsen FC. De novo mutations in familial adenomatous polyposis (FAP). Eur J Hum Genet 2002; 10: 631-637.
17. van Minkelen R, van Bever Y, Kromosoeto JN, Withagen-Hermans CJ, Nieuwlaat A, Halley DJ, et al. A clinical and genetic overview of 18 years neurofibromatosis type 1 molecular diagnostics in the Netherlands. Clin Genet 2014; 85: 318-327.
18. Houdayer C, Gauthier-Villars M, Castéra L, Desjardins L, Doz F, Stoppa-Lyonnet DRetinoblastoma-genetic counseling and molecular diagnosis. In: Kumaramanickavel G (ed). Retinoblastoma: An Update on Clinical, Genetic Counseling, Epidemiology and Molecular Tumor Biology. InTech: Rijeka, Croatia, 2012, pp 55-73.
19. Bonaïti B, Alarcon F, Andrieu N, Bonadona V, Dondon MG, Pennec S, et al. A new scoring system in cancer genetics: application to criteria for BRCA1 and BRCA2 mutation screening. J Med Genet 2014; 51: 114-121.
20. Zhang L, Fleischut MH, Kohut K, Spencer S, Wong K, Stadler ZK, et al. Assessment of the prevalence of de novo mutations in the BRCA1 and BRCA2 genes. Clin Genet 2011; 80: 97-98.
21. Hodgkinson A, Eyre-Walker A. Variation in the mutation rate across mammalian genomes. Nat Rev Genet 2011; 12: 756-766.
22. Caux-Moncoutier V, Castéra L, Tirapo C, Michaux D, Rémon MA, Laugé A, et al. EMMA, a cost-And time-Effective diagnostic method for simultaneous detection of point mutations and large-scale genomic rearrangements: application to BRCA1 and BRCA2 in 1525 patients. Hum Mutat 2011; 32: 325-334.
23. Veltman JA, Brunner HG. De novo mutations in human genetic disease. Nat Rev Genet 2012; 13: 565-575.
24. Pal T, Keefe D, Sun P, Narod SAHereditary Breast Cancer Clinical Study Group, Fertility in women with BRCA mutations: a case-control study Fertil Steril 2010; 93: 1805-1808
25. Friedman E, Kotsopoulos J, Lubinski J, Lynch HT, Ghadirian P, Neuhausen SL. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res 2006; 8: R15.
26. Moslehi R, Singh R, Lessner L, Friedman JM. Impact of BRCA mutations on female fertility and offspring sex ratio. Am J Hum Biol 2010; 22: 201-205.
27. Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002; 86: 76-83.
28. Biesecker LG, Spinner NB. A genomic view of mosaicism and human disease. Nat Rev Genet 2013; 14: 307-320.
29. Walsh T, Lee MK, Casadei S, Thornton AM, Stray SM, Pennil C, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci USA 2010; 107: 12629-12633.
30. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. Oncogene 2006; 25: 5898-5905.
31. Tarabeux J, Zeitouni B, Moncoutier V, Tenreiro H, Abidallah K, Lair S, et al. Streamlined ion torrent PGM-based diagnostics: BRCA1 and BRCA2 genes as a model. Eur J Hum Genet 2014; 22: 535-541.
32. Rouleau E, Lefol C, Tozlu S, Andrieu C, Guy C, Copigny F, et al. High-resolution oligonucleotide array-CGH applied to the detection and characterization of large rearrangements in the hereditary breast cancer gene BRCA1. Clin Genet 2007; 72: 199-207.